Koren Gideon
J Popul Ther Clin Pharmacol. 2014;21(3):e518-9. Epub 2013 Dec 1.
With children being largely orphaned from the benefits of drugs, and being managed mostly by medications unapproved by Health Canada, a landmark document was published in September 2014 by the Council of Canadian Academies (CCA) to serve as a blueprint to change this grim reality. The main findings of the panel included: 1. Children take medications, many of which have not been proven safe and effective for their use. 2. Children respond to medications differently from adults; thus, medicines must be studied in children and formulated for children. 3. Studying medicines in children is always possible and in their best interests. 4. In the United States and the European Union, pediatric medicines research is encouraged, required and monitored in ways that offer lessons for Canada. 5. Pediatric medicines research is a Canadian strength, but it requires reinforcement, sustained capacity and infrastructure to realize its full potential.
由于儿童基本上无法从药物的益处中受益，且大多使用未经加拿大卫生部批准的药物进行治疗，加拿大科学院理事会（CCA）于2014年9月发布了一份具有里程碑意义的文件，作为改变这一严峻现实的蓝图。该小组的主要调查结果包括：1. 儿童服用药物，其中许多药物尚未被证明对其使用是安全有效的。2. 儿童对药物的反应与成人不同；因此，必须针对儿童进行药物研究并为儿童配制药物。3. 对儿童进行药物研究总是可行的，且符合他们的最大利益。4. 在美国和欧盟，儿科药物研究受到鼓励、要求并受到监管，这些方式可为加拿大提供借鉴。5. 儿科药物研究是加拿大的优势，但需要加强、持续的能力和基础设施，以充分发挥其潜力。
